Literature DB >> 15495056

Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years.

W R Craig1, A Hanlon-Dearman, C Sinclair, S Taback, M Moffatt.   

Abstract

BACKGROUND: Gastro-esophageal reflux (GER) is the refluxing of gastric contents into the esophagus. Fifty per cent of all infants 0 to 3 months regurgitate at least once a day. This drops to 5% once infants are 10 to 12 months old. Three per cent of parents of 10 to 12 month old infants view this as a problem.
OBJECTIVES: To investigate the effectiveness of thickened feeds, positioning, and metoclopramide as compared to placebo in improving the outcome of GER in developmentally normal infants aged one month to two years. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2003), MEDLINE (January 1966 to 23 January 2003), EMBASE (January 1985 to 27 January 2003), and reference lists of articles. SELECTION CRITERIA: Randomised studies (parallel or cross over) which evaluated thickened feeds, positional alternations or metoclopramide for the treatment of GER in children between the age of one month and two years who were developmentally normal. DATA COLLECTION AND ANALYSIS: All three reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN
RESULTS: Twenty trials involving 771 children met the inclusion criteria: eight dealt with thickened feeds, five with positioning, and seven with metoclopramide. Few comparisons could be made, and so summary measures were often made with two or three studies. Thickened feeds reduce the regurgitation severity score (standardized mean difference (SMD) -0.94;95% confidence interval -1.35 to -0.52), as well as the frequency of emesis (SMD -0.91; confidence interval -1.22 to -0.61). The reflux index was not reduced (weighted mean difference (WMD) 0.48%; 95% confidence interval-3.27 to 4.23). All five positioning studies utilized esophageal pH monitoring as their outcome measure. Elevating the head of the crib for treating reflux in the supine position is not justifiable. The seven metoclopramide studies used a variety of outcomes. Compared to placebo, metoclopramide appears to reduce daily symptoms ( SMD -0.73; 95% confidence interval -1.16 to -0.30), and reduce the reflux index (WMD -2.80%; 95% confidence interval -5.58 to -0.01). It does increase side effects. REVIEWERS'
CONCLUSIONS: Thickened feeds are helpful in reducing the symptoms of GER. Elevating the head of the crib in the supine position does not have any effect. Metoclopramide may have some benefit in comparison to placebo in the symptomatic treatment for GER, but that must be weighed against possible side effects. .

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15495056     DOI: 10.1002/14651858.CD003502.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  15 in total

Review 1.  Healthcare-associated infection prevention in pediatric intensive care units: a review.

Authors:  N Joram; L de Saint Blanquat; D Stamm; E Launay; C Gras-Le Guen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-01       Impact factor: 3.267

Review 2.  The current role of laparoscopic surgery for gastroesophageal reflux disease in infants and children.

Authors:  T E Lobe
Journal:  Surg Endosc       Date:  2007-01-02       Impact factor: 4.584

Review 3.  A review of nonsurgical treatment for the symptom of irritability in infants with GERD.

Authors:  Madalynn Neu; Elizabeth Corwin; Suzanne C Lareau; Cassandra Marcheggiani-Howard
Journal:  J Spec Pediatr Nurs       Date:  2011-11-01       Impact factor: 1.260

Review 4.  Feed thickener for infants up to six months of age with gastro-oesophageal reflux.

Authors:  T'ng Chang Kwok; Shalini Ojha; Jon Dorling
Journal:  Cochrane Database Syst Rev       Date:  2017-12-05

5.  Pediatric specialists' beliefs about gastroesophageal reflux disease in premature infants.

Authors:  Catherine A Golski; Ellen S Rome; Richard J Martin; Scott H Frank; Sarah Worley; Zhiyuan Sun; Anna Maria Hibbs
Journal:  Pediatrics       Date:  2009-12-14       Impact factor: 7.124

Review 6.  Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Authors:  Mark P Tighe; Nadeem A Afzal; Amanda Bevan; R Mark Beattie
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

7.  Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole.

Authors:  Elizabet V Guimarães; Paula Vp Guerra; Francisco J Penna
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 8.  Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

Authors:  Shlomi Cohen; Mirjam Bueno de Mesquita; Francis B Mimouni
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

9.  Management of a child with vomiting.

Authors:  Sunit C Singhi; Ravi Shah; Arun Bansal; M Jayashree
Journal:  Indian J Pediatr       Date:  2013-01-23       Impact factor: 1.967

Review 10.  Pharmacological treatment of children with gastro-oesophageal reflux.

Authors:  Mark Tighe; Nadeem A Afzal; Amanda Bevan; Andrew Hayen; Alasdair Munro; R Mark Beattie
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.